Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Aytu Biopharma (AYTU) Preferred Shares Issued (2020)

Aytu Biopharma has reported Preferred Shares Issued over the past 1 years, most recently at $6.7 million for Q2 2020.

Quarterly Preferred Shares Issued changed N/A to $6.7 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $55.7 million through Jun 2020, changed N/A year-over-year, with the annual reading at $65.7 million for FY2020, 333.0% up from the prior year.
Preferred Shares Issued was $6.7 million for Q2 2020 at Aytu Biopharma, down from $49.0 million in the prior quarter.
Over five years, Preferred Shares Issued peaked at $49.0 million in Q1 2020 and troughed at $6.7 million in Q2 2020.